摘要
目的:研究聚乙二醇干扰素α-2a注射液(派罗欣)联合利巴韦林治疗慢性丙肝临床效果。方法:选择笔者所在医院2014年1月-2016年6月诊疗的慢性丙肝患者55例,依据随机分配的原理,将其中27例患者作为A组,实施利巴韦林联合干扰素治疗;28例患者作为B组,实施派罗欣联合利巴韦林治疗,对比分析两组患者临床疗效与不良反应。结果:A组患者临床总有效率为70.37%,B组患者临床总有效率为96.43%,A组患者临床总有效率低于B组患者,两组患者临床疗效对比差异有统计学意义(P<0.05)。A组患者药物不良反应为55.55%,B组患者药物不良反应为32.14%,A组患者药物不良反应虽高于B组患者,但差异无统计学意义(P>0.05)。结论:慢性丙肝临床治疗中,派罗欣联合利巴韦林治疗手段的运用,既可促进临床疗效的提升,又可降低患者药物不良反应,值得推广。
Objective：To study the curative effect of Pegasys united Ribavirin in the treatment of chronic hepatitis C.Method：fifty-five patients with chronic hepatitis c were selected from the hospital from January 2014 to June 2016.According to the principle of random assignment,27 patients were in group A,and the treatment of Interferon and Ribavirin were performed.The 28 patients were in group B,and the treatment of Pegasys combined with Ribavirin were performed,and the clinical efficacy and adverse reactions of the two groups were compared and analyzed.Result：The clinical total effective rate was 70.37% in group A patients,group B patients clinical total effective rate was 96.43%,group A of patients clinical total effective rate was lower than that of group B patients,there was statistically significant（P0.05）.Group A of patients with adverse drug reactions was 55.55%,group B of patients with drug adverse reaction was 32.14%,the patients of group A was significantly higher than that of group B patients of adverse drug reactions,there was no statistical significance（P0.05）.Conclusion：In the clinical treatment of chronic hepatitis C,the application of the combination of the treatment of Pegasys and Ribavirin can promote the improvement of clinical efficacy and reduce the adverse drug reaction of patients,which is worth promoting.
出处
《中外医学研究》
2018年第5期1-3,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
派罗欣
利巴韦林
慢性丙肝
Pegasys
Ribavirin
Chronic hepatitis C
